Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2021

13.04.2021

Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial

verfasst von: M. Verdoia, H. Suryapranata, S. Damen, C. Camaro, E. Benit, L. Barbieri, S. Rasoul, H. B. Liew, J. Polad, W. A. W. Ahmad, R. Zambahari, J. Lalmand, R. J. van der Schaaf, T. H. Koh, P Timmermans Sr., D. Dilling-Boer, L. F. Veenstra, A. W. J. van’t Hof, S. W. L. Lee, V. Roolvink, E. Ligtenberg, S. Postma, E. J. J. Kolkman, M. A. Brouwer, E. Kedhi, G. De Luca

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Gender differences in the thrombotic and bleeding risk have been suggested to condition the benefits of antithrombotic therapies in Acute Coronary Syndrome (ACS) patients, and mainly among those undergoing percutaneous coronary interventions with drug eluting stents (DES). The impact of gender on the optimal duration of dual antiplatelet therapy (DAPT) in ACS patients is still unexplored and was, therefore, the aim of the present sub-study.

Methods

REDUCE was a prospective, multicenter, randomized investigator-initiated study designed to enroll 1500 ACS patients after treatment with the COMBO Dual Stent Therapy, based on a noninferiority design. Patients were randomized in a 1:1 fashion to either 3 or 12 months of DAPT. Primary study endpoint was a composite of all-cause mortality, myocardial infarction, definite/probable stent thrombosis (ST), stroke, target-vessel revascularization (TVR) and bleedings (BARC II, III, V) at 12 months. Secondary endpoints were cardiovascular mortality and the individual components of the primary endpoint within 24 months.

Results

From June 2014 to May 2016 300 women and 1196 men were included in the study. Among them, 43.7% of females and 51.9% of males were assigned to the 3 months DAPT treatment. Baseline characteristics were well matched between the two arms, with the exception of a lower rate of TIMI flow < 3 (p = 0.04), lower systolic blood pressure (p = 0.05) and use of spironolactone (p = 0.006) among women and a more advanced age (p = 0.05) among men receiving a short-term DAPT. At a mean follow-up of 525 (± 198) days, no difference in the primary endpoint was observed according to DAPT duration in both females [6.9% vs 5.9%, HR (95% CI) = 1.19 (0.48–2.9), p = 0.71] and males [8.2% vs 9%, HR (95% CI) = 0.92 (0.63–1.35), p = 0.67; p INT = 0.20]. Results were confirmed after correction for baseline differences [females: adjusted HR (95% CI) = 1.12 (0.45–2.78), p = 0.81; males: adjusted HR (95% CI) = 0.90 (0.61–1.32), p = 0.60]. Comparable rates of survival, thrombotic (MI, stent thrombosis, TVR, stroke) and bleeding events were observed with the two DAPT strategies, with no impact of gender.

Conclusions

The present study shows that among ACS patients randomized in the REDUCE trial, a 3 months DAPT strategy offers comparable results as compared to a standard 12 months DAPT at 2-years follow-up in both male and female gender.
Literatur
1.
Zurück zum Zitat Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2015) Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. Nutr Metab Cardiovasc Dis 25(5):464–470PubMedCrossRef Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2015) Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. Nutr Metab Cardiovasc Dis 25(5):464–470PubMedCrossRef
2.
Zurück zum Zitat Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2015) Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: a single-centre study. Atherosclerosis 241(1):241PubMedCrossRef Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2015) Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: a single-centre study. Atherosclerosis 241(1):241PubMedCrossRef
3.
Zurück zum Zitat Barbieri L, Verdoia M, Nardin M, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2017) Gender difference in the risk of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous coronary intervention. Angiology 68(6):542–546PubMedCrossRef Barbieri L, Verdoia M, Nardin M, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2017) Gender difference in the risk of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous coronary intervention. Angiology 68(6):542–546PubMedCrossRef
4.
Zurück zum Zitat Cenko E, Yoon J, Kedev S, Stankovic G, Vasiljevic Z, Krljanac G, Kalpak O, Ricci B, Milicic D, Manfrini O, van der Schaar M, Badimon L, Bugiardini R (2018) Sex differences in outcomes after STEMI: effect modification by treatment strategy and age. JAMA Intern Med 178(5):632–639PubMedPubMedCentralCrossRef Cenko E, Yoon J, Kedev S, Stankovic G, Vasiljevic Z, Krljanac G, Kalpak O, Ricci B, Milicic D, Manfrini O, van der Schaar M, Badimon L, Bugiardini R (2018) Sex differences in outcomes after STEMI: effect modification by treatment strategy and age. JAMA Intern Med 178(5):632–639PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat De Luca G, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F, Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K, van’t Hof AW (2010) Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis 30(3):342–346. https://doi.org/10.1007/s11239-010-0451-yCrossRefPubMed De Luca G, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F, Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K, van’t Hof AW (2010) Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis 30(3):342–346. https://​doi.​org/​10.​1007/​s11239-010-0451-yCrossRefPubMed
6.
Zurück zum Zitat De Luca G, Verdoia M, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, Hoeven BV, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, de la Llera LSD, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW, DESERT Cooperation (2013) Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the DESERT cooperation. Atherosclerosis 230(1):12–16PubMedCrossRef De Luca G, Verdoia M, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, Hoeven BV, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, de la Llera LSD, Pasceri V, Di Lorenzo E, Violini R, Suryapranata H, Stone GW, DESERT Cooperation (2013) Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the DESERT cooperation. Atherosclerosis 230(1):12–16PubMedCrossRef
7.
Zurück zum Zitat De Luca G, Biondi-Zoccai G, Marino P (2008) Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. Ann Emerg Med 52(6):665–676PubMedCrossRef De Luca G, Biondi-Zoccai G, Marino P (2008) Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. Ann Emerg Med 52(6):665–676PubMedCrossRef
8.
Zurück zum Zitat De Luca G, Smits P, Hofma SH, Di Lorenzo E, Vlachojannis GJ, Van’t Hof AWJ, van Boven AJ, Kedhi E, Stone GW, Suryapranata H, Drug-Eluting Stent in Primary Angioplasty (DESERT 3) cooperation (2017) Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Int J Cardiol 244:121–127PubMedCrossRef De Luca G, Smits P, Hofma SH, Di Lorenzo E, Vlachojannis GJ, Van’t Hof AWJ, van Boven AJ, Kedhi E, Stone GW, Suryapranata H, Drug-Eluting Stent in Primary Angioplasty (DESERT 3) cooperation (2017) Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Int J Cardiol 244:121–127PubMedCrossRef
9.
Zurück zum Zitat De Luca G, Navarese EP, Suryapranata H (2013) A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 166:606–612PubMedCrossRef De Luca G, Navarese EP, Suryapranata H (2013) A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 166:606–612PubMedCrossRef
10.
Zurück zum Zitat De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, van’t Hof AW (2005) Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 93(5):820–823PubMedCrossRef De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, van’t Hof AW (2005) Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 93(5):820–823PubMedCrossRef
12.
Zurück zum Zitat Pancholy SB, Shantha GP, Patel T, Cheskin LJ (2014) Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. JAMA Intern Med 174:1822–1830PubMedCrossRef Pancholy SB, Shantha GP, Patel T, Cheskin LJ (2014) Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. JAMA Intern Med 174:1822–1830PubMedCrossRef
13.
Zurück zum Zitat De Luca G, Parodi G, Sciagrà R, Bellandi B, Verdoia M, Vergara R, Migliorini A, Valenti R, Antoniucci D (2013) Relation of gender to infarct size in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol 111(7):936–940PubMedCrossRef De Luca G, Parodi G, Sciagrà R, Bellandi B, Verdoia M, Vergara R, Migliorini A, Valenti R, Antoniucci D (2013) Relation of gender to infarct size in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol 111(7):936–940PubMedCrossRef
14.
Zurück zum Zitat De Luca G, Suryapranata H, Dambrink JH, Ottervanger JP, van’t Hof AW, Zijlstra F, Hoorntje JC, Gosselink AT, de Boer MJ (2004) Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction study. Am Heart J 148:852–856PubMedCrossRef De Luca G, Suryapranata H, Dambrink JH, Ottervanger JP, van’t Hof AW, Zijlstra F, Hoorntje JC, Gosselink AT, de Boer MJ (2004) Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction study. Am Heart J 148:852–856PubMedCrossRef
15.
Zurück zum Zitat De Luca G, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Zijlstra F, de Boer MJ, Suryapranata H (2005) Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 150(3):557–562PubMedCrossRef De Luca G, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Zijlstra F, de Boer MJ, Suryapranata H (2005) Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 150(3):557–562PubMedCrossRef
16.
Zurück zum Zitat Mohamed MO, Rashid M, Timmis A, Clarke S, Lawson C, Michos ED, Kwok CS, De Belder M, Valgimigli M, Mamas MA (2020) Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. Int J Cardiol S0167–5273(20):34311–34314 Mohamed MO, Rashid M, Timmis A, Clarke S, Lawson C, Michos ED, Kwok CS, De Belder M, Valgimigli M, Mamas MA (2020) Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. Int J Cardiol S0167–5273(20):34311–34314
17.
Zurück zum Zitat Khan E, Brieger D, Amerena J, Atherton JJ, Chew DP, Farshid A, Ilton M, Juergens CP, Kangaharan N, Rajaratnam R, Sweeny A, Walters DL, Chow CK (2018) Differences in management and outcomes for men and women with ST-elevation myocardial infarction. Med J Aust 209(3):118–123PubMedCrossRef Khan E, Brieger D, Amerena J, Atherton JJ, Chew DP, Farshid A, Ilton M, Juergens CP, Kangaharan N, Rajaratnam R, Sweeny A, Walters DL, Chow CK (2018) Differences in management and outcomes for men and women with ST-elevation myocardial infarction. Med J Aust 209(3):118–123PubMedCrossRef
18.
Zurück zum Zitat D’Ascenzo F, Colombo F, Barbero U, Moretti C, Omedè P, Reed MJ, Tarantini G, Frati G, Di Nicolantonio JJ, Biondi Zoccai G, Gaita F (2014) Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis. J Interv Cardiol 27(3):233–241PubMedCrossRef D’Ascenzo F, Colombo F, Barbero U, Moretti C, Omedè P, Reed MJ, Tarantini G, Frati G, Di Nicolantonio JJ, Biondi Zoccai G, Gaita F (2014) Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis. J Interv Cardiol 27(3):233–241PubMedCrossRef
19.
Zurück zum Zitat Haude M, Lee SW, Worthley SG et al (2013) The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC cardiovasc interv 6:334–343PubMedCrossRef Haude M, Lee SW, Worthley SG et al (2013) The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC cardiovasc interv 6:334–343PubMedCrossRef
20.
Zurück zum Zitat Palmerini T, Della Riva D, Benedetto U et al (2017) Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11473 patients. Eur Heart J 38:1034–1043PubMedPubMedCentral Palmerini T, Della Riva D, Benedetto U et al (2017) Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11473 patients. Eur Heart J 38:1034–1043PubMedPubMedCentral
21.
Zurück zum Zitat Verdoia M, Kedhi E, Ceccon C, Suryapranata H, De Luca G (2018) Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: a meta-analysis of 11 randomized trials. Int J Cardiol 264:30–38PubMedCrossRef Verdoia M, Kedhi E, Ceccon C, Suryapranata H, De Luca G (2018) Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: a meta-analysis of 11 randomized trials. Int J Cardiol 264:30–38PubMedCrossRef
22.
Zurück zum Zitat Nakazawa G, Granada JF, Alviar CL et al (2010) Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 3:68–75PubMedCrossRef Nakazawa G, Granada JF, Alviar CL et al (2010) Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 3:68–75PubMedCrossRef
23.
Zurück zum Zitat Räber L, Zanchin T, Baumgartner S et al (2014) Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study. Int J Cardiol 173:259–267PubMedCrossRef Räber L, Zanchin T, Baumgartner S et al (2014) Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study. Int J Cardiol 173:259–267PubMedCrossRef
24.
Zurück zum Zitat De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, Postma S, Kedhi E, Suryapranata H, Collaborators (2019) Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial. EuroIntervention. https://doi.org/10.4244/EIJ-D-19-00539 (Epub ahead of print)CrossRefPubMed De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, Postma S, Kedhi E, Suryapranata H, Collaborators (2019) Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial. EuroIntervention. https://​doi.​org/​10.​4244/​EIJ-D-19-00539 (Epub ahead of print)CrossRefPubMed
25.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS et al (2012) Joint ESC/ACCF/AHA/WHF task force for the universal definition of myocardial infarction. Third universal definition of myocardial infarction. Circulation 126:2020–2035PubMedCrossRef Thygesen K, Alpert JS, Jaffe AS et al (2012) Joint ESC/ACCF/AHA/WHF task force for the universal definition of myocardial infarction. Third universal definition of myocardial infarction. Circulation 126:2020–2035PubMedCrossRef
26.
Zurück zum Zitat Cutlip DE, Windecker S, Mehran R, Academic Research Consortium et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef Cutlip DE, Windecker S, Mehran R, Academic Research Consortium et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef
27.
Zurück zum Zitat Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747PubMedCrossRef Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747PubMedCrossRef
28.
Zurück zum Zitat Camaro C, Damen SA, Brouwer MA et al (2016) Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. Am Heart J 178:37–44PubMedCrossRef Camaro C, Damen SA, Brouwer MA et al (2016) Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. Am Heart J 178:37–44PubMedCrossRef
29.
Zurück zum Zitat Verdoia M, Schaffer A, Barbieri L, Montalescot G, Collet JP, Colombo A, Suryapranata H, De Luca G (2016) Optimal duration of dual antiplatelet therapy after DES implantation: a meta-analysis of 11 randomized trials. Angiology 67(3):224–238PubMedCrossRef Verdoia M, Schaffer A, Barbieri L, Montalescot G, Collet JP, Colombo A, Suryapranata H, De Luca G (2016) Optimal duration of dual antiplatelet therapy after DES implantation: a meta-analysis of 11 randomized trials. Angiology 67(3):224–238PubMedCrossRef
30.
Zurück zum Zitat Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166PubMedPubMedCentralCrossRef Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Bonaca MP, Bhatt DL, Cohen M, PEGASUS-TIMI 54 Steering Committee and Investigators (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800PubMedCrossRef Bonaca MP, Bhatt DL, Cohen M, PEGASUS-TIMI 54 Steering Committee and Investigators (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800PubMedCrossRef
32.
Zurück zum Zitat Didier R, Morice MC, Barragan P et al (2017) 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for des after discontinuation of clopidogrel). JACC Cardiovasc Interv 10:1202–1210PubMedCrossRef Didier R, Morice MC, Barragan P et al (2017) 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for des after discontinuation of clopidogrel). JACC Cardiovasc Interv 10:1202–1210PubMedCrossRef
33.
Zurück zum Zitat Verdoia M, Schaffer A, Barbieri L et al (2014) Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. J Cardiovasc Pharmacol 63:339–350PubMedCrossRef Verdoia M, Schaffer A, Barbieri L et al (2014) Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. J Cardiovasc Pharmacol 63:339–350PubMedCrossRef
34.
Zurück zum Zitat Palmerini T, Reggiani LB, Riva DD et al (2017) Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting. J Am Coll Cardiol 69:2011–2022PubMedCrossRef Palmerini T, Reggiani LB, Riva DD et al (2017) Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting. J Am Coll Cardiol 69:2011–2022PubMedCrossRef
35.
Zurück zum Zitat Benenati S, Crimi G, Canale C, Pescetelli F, De Marzo V, Vergallo R, Galli M, Della Bona R, Canepa M, Ameri P, Crea F, Porto I (2020) Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network meta-analysis. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvaa127CrossRef Benenati S, Crimi G, Canale C, Pescetelli F, De Marzo V, Vergallo R, Galli M, Della Bona R, Canepa M, Ameri P, Crea F, Porto I (2020) Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network meta-analysis. Eur Heart J Cardiovasc Pharmacother. https://​doi.​org/​10.​1093/​ehjcvp/​pvaa127CrossRef
36.
Zurück zum Zitat Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, Bona RD, Canepa M, Ameri P, Crea F, Porto I (2020) Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvaa001CrossRef Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, Bona RD, Canepa M, Ameri P, Crea F, Porto I (2020) Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Pharmacother. https://​doi.​org/​10.​1093/​ehjcvp/​pvaa001CrossRef
37.
Zurück zum Zitat Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S (2016) Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67(19):2224–2234PubMedCrossRef Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S (2016) Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67(19):2224–2234PubMedCrossRef
38.
Zurück zum Zitat Gutiérrez-Chico JL, Mehilli J (2013) Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention. Drugs 73(17):1921–1933PubMedCrossRef Gutiérrez-Chico JL, Mehilli J (2013) Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention. Drugs 73(17):1921–1933PubMedCrossRef
39.
Zurück zum Zitat Russ MA, Wackerl C, Zeymer U, Hochadel M, Kerber S, Zahn R, Zrenner B, Topp H, Schächinger V, Weber MA, ALKK-Study Group (2017) Gender based differences in drug eluting stent implantation—data from the German ALKK registry suggest underuse of DES in elderly women. BMC Cardiovasc Disord 17(1):68PubMedPubMedCentralCrossRef Russ MA, Wackerl C, Zeymer U, Hochadel M, Kerber S, Zahn R, Zrenner B, Topp H, Schächinger V, Weber MA, ALKK-Study Group (2017) Gender based differences in drug eluting stent implantation—data from the German ALKK registry suggest underuse of DES in elderly women. BMC Cardiovasc Disord 17(1):68PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Alabas OA, Gale CP, Hall M, Rutherford MJ, Szummer K, Lawesson SS, Alfredsson J, Lindahl B, Jernberg T (2017) Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry. J Am Heart Assoc 61:2 Alabas OA, Gale CP, Hall M, Rutherford MJ, Szummer K, Lawesson SS, Alfredsson J, Lindahl B, Jernberg T (2017) Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry. J Am Heart Assoc 61:2
42.
Zurück zum Zitat Numasawa Y, Inohara T, Ishii H, Kuno T, Kodaira M, Kohsaka S, Fujii K, Uemura S, Amano T, Kadota K, Nakamura M (2017) Comparison of outcomes of women versus men with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the Japanese nationwide registry). Am J Cardiol 119(6):826–831PubMedCrossRef Numasawa Y, Inohara T, Ishii H, Kuno T, Kodaira M, Kohsaka S, Fujii K, Uemura S, Amano T, Kadota K, Nakamura M (2017) Comparison of outcomes of women versus men with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the Japanese nationwide registry). Am J Cardiol 119(6):826–831PubMedCrossRef
43.
Zurück zum Zitat Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L, PLATO study group (2014) The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 35(23):1541–1550PubMedPubMedCentralCrossRef Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L, PLATO study group (2014) The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 35(23):1541–1550PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Wiviott SD, Braunwald E, McCabe CH, TRITON-TIMI 38Investigators et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRef Wiviott SD, Braunwald E, McCabe CH, TRITON-TIMI 38Investigators et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRef
45.
Zurück zum Zitat Yu J, Mehran R, Baber U, Ooi SY, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Maehara A, Xu K, Ben-Yehuda O, Kirtane AJ, Stone GW (2017) Sex differences in the clinical impact of high platelet reactivity after percutaneous coronary intervention with drug-eluting stents: results from the ADAPT-DES study (assessment of dual antiplatelet therapy with drug-eluting stents). Circ Cardiovasc Interv. https://doi.org/10.1161/CIRCINTERVENTIONS.116.003577CrossRefPubMed Yu J, Mehran R, Baber U, Ooi SY, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Maehara A, Xu K, Ben-Yehuda O, Kirtane AJ, Stone GW (2017) Sex differences in the clinical impact of high platelet reactivity after percutaneous coronary intervention with drug-eluting stents: results from the ADAPT-DES study (assessment of dual antiplatelet therapy with drug-eluting stents). Circ Cardiovasc Interv. https://​doi.​org/​10.​1161/​CIRCINTERVENTION​S.​116.​003577CrossRefPubMed
46.
Zurück zum Zitat Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2016) Gender differences in platelet reactivity in patients receiving dual antiplatelet therapy. Cardiovasc Drugs Ther 30(2):143–150PubMedCrossRef Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS) (2016) Gender differences in platelet reactivity in patients receiving dual antiplatelet therapy. Cardiovasc Drugs Ther 30(2):143–150PubMedCrossRef
47.
Zurück zum Zitat Giustino G, Redfors B, Mehran R, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Dangas GD, Brener SJ, Ozgu Ozan M, Stone GW (2017) Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: from the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Int J Cardiol 246:20–25PubMedCrossRef Giustino G, Redfors B, Mehran R, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Brodie BR, Stuckey TD, Dangas GD, Brener SJ, Ozgu Ozan M, Stone GW (2017) Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: from the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Int J Cardiol 246:20–25PubMedCrossRef
48.
Zurück zum Zitat Mehta SR, Yusuf S, Peters RJ, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef Mehta SR, Yusuf S, Peters RJ, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef
Metadaten
Titel
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial
verfasst von
M. Verdoia
H. Suryapranata
S. Damen
C. Camaro
E. Benit
L. Barbieri
S. Rasoul
H. B. Liew
J. Polad
W. A. W. Ahmad
R. Zambahari
J. Lalmand
R. J. van der Schaaf
T. H. Koh
P Timmermans Sr.
D. Dilling-Boer
L. F. Veenstra
A. W. J. van’t Hof
S. W. L. Lee
V. Roolvink
E. Ligtenberg
S. Postma
E. J. J. Kolkman
M. A. Brouwer
E. Kedhi
G. De Luca
Publikationsdatum
13.04.2021
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2021
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02439-x

Weitere Artikel der Ausgabe 3/2021

Journal of Thrombosis and Thrombolysis 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.